

**REMARKS**

Reconsideration of the application is respectfully requested in light of the amendments herein and remarks thereto.

Claims 21 and 22 were indicated as allowable.

Claims 2, 4-8 and 11 were indicated as allowable if rewritten independent form.

Claims 2, 19 and 20 have been cancelled.

Claim 12 has been rewritten to incorporate the subject matter of claim 2 (now cancelled). Accordingly, claims 3-11 appended, directly or indirectly to claim 12, are now patentable by virtue of their dependency from a patentable base claim, claim 12.

Claims 13 and 17 each have been rewritten to incorporate the subject matter of claim 2 (now cancelled) and each corresponds substantially to claim 12. Accordingly, amended claims 13 and 17 are allowable, and claims 15 and 16 appended to amended claim 17 are allowable.

In view of the above, allowance of pending claims 3-13, 15-17 and 21-22 is requested.

Authorization is hereby given to charge any fees which may be required, except the issue fee, to Deposit Account 14-0627.

Respectfully submitted,

s/Joseph Kolodka/

Joseph J. Kolodka  
Registration No. 39,731  
Tel. No. 609 951-2522

August 3, 2007

NEC Laboratories America, Inc.  
4 Independence Way  
Princeton, NJ 08540  
Tel No. 609 951-2522  
Fax No. 609 951-2480